Evaluation of a Novel Bayesian Method for Individualizing Theophylline Dosage by STEIN, U. et al.
Stein et al.: Novel Bayesian method for individualizing theophylline dosage 405
J. Clin. Chem. Clin. Biochem.
Vol. 26, 1988, pp. 405-414
© 1988 Walter de Gruyter & Co.
Berlin · New York
Evaluation of a Novel Bayesi&n Method for Individualizing
Theophylline Dosage1)
By U. Stein2), M. Oellerich
Institut för Klinische Chemie, Medizinische Hochschule Hannover, Federal Republic of Germany
G. W. Sybrecht
Abteilung Pneumonologiet Medizinische Universitätsklinik Homburg/Saar, Federal Republic of Germany and
B. Schneider
Institut för Biometrie, Medizinische Hochschule Hannover, Federal Republic of Germany
(Received September 8, 1987/February 25, 1988)
Summary: A novel Bayesian drug dosing program (Abbott Pharmacokinetic Systems, Theophylline Program)
was evaluated. The predictive accuracy of this method was assessed in 10 healthy volunteers receiving single
intravenous test doses. Estimates for clearance and distribution volume were compared with those obtained
from the area under the curve. The observed prediction error depended largely on sampling time. The
deviations were lowest for the distribution volume during the first 60 min and for clearance at 12 hours after
theophylline administration. Furthermore the Bayesian technique was prospectively evaluated in 10 hospital-
ized and 22 outpatients treated with sustained-release theophylline preparations (Uniphyllin, Bronchoretard,
PulmiDur). Predictive precision and accuracy were adequate, if theophylline was given twice daily. The highest
predictive accuracy was achieved in outpatients, if predictions were based on trough concentrations. In 19/22
outpatients prediction errors were within a clinically acceptable range (mean prediction error + standard
deviation; —0.6 ± 2.1 mg/1). Moreover in hospitalized patients (n = 5) with twice-daily maintenance regimens,
concentration-time curves could mainly be predicted with sufficient accuracy. Hospitalized patients (n = 5)
with once-daily dosing showed large fluctuations between peak and trough theophylline concentrations in
serum. In these patients a reliable prediction of the concentration-time curves was not possible apparently
due to non-linearity of theophylline kinetics. Relatively large prediction errors were found in one patient with
acute viral respiratory illness and 3 patients with altered absorption. Despite certain limitations the clinical
application of the Bayesian forecasting method tested appears to be promising.
Introduction clearance, attempts to individualize dosage regimens
have been made in order to avoid inadequate or toxic
Theophylline, which is frequently used in the treat^
 senjm concentrations of 8 drug.
ment of reversible obstructive airways disease, shows
a low toxic/therapeutic ratio. Since there is wide inter- The frequency distribution of theophylline values in
and intraindividual variability (1) in theophylline patients treated in our hospital during the years 1978
——^_^_ to 1986 cieary indicates the difficulty of achieving the
*) Preliminary results of this study were presented at the Sym- optimal dose for this drug (fig. 1). Only about 37 to
posium Klinisch-Toxikologische Analytik in Salzburg 1987 54
 per cent of the theophylline concentrations deter-(Abstract: J. Clin. Chem. Clin. Biochem. 25, 622-623 . , ... .- *V; ,. rp, ^(1987)), mined were within the therapeutic range. The con-
2) In fulfillment of his thesis (Dr. med.) sistently high percentage of theophylline concentra-
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Fig. 1. Frequency distribution of all theophylline concentrations determined in samples from patients with obstructive respiratory
disorders treated at our clinic during the years 1978 — 1986. Concentration ranges:
A: < 2.5( ing/1; B: 2.6-7.9 mg/1; C: 8.0-20.0 mg/1; D: > 20.0 mg/1
tions in the subtherapeutic range is noteworthy. In
these patients pharmacokinetic dose prediction meth-
ods were not routinely used for individual dosage
adjustment.
Usually theophylline serum concentrations from ther-
apeutic drug monitoring are only used in a "trial and
error" fashion to optimize the patients dosage regi-
men. A more rapid and effective way of individual-
izing theophylline dosage is to use appropiate phar-
macokinetic methods for dose prediction (2 — 9). The
Bayesian approach combines a priori information on
population distribution of pharmacokinetic parame-
ters with data on one or more actually measured
serum theophylline concentrations in estimating the
individual patient's clearance and distribution volume
(2, 8).
This prospective study was designed to evaluate the
performance of a novel Bayesi&n dosage prediction
method (Abbott Pharmacokinetic Systems; Theo-
phylline Program) in outpatients and hospitalized pa-
tients with obstructive respiratory disease. Moreover,
the predictive accuracy of this method for estimating
clearance and distribution volume was tested with
data from healthy volunteers.
Study Design
The pharmacokinetics of theophylline were studied in 10
healthy volunteers and in 10 hospitalized and 22 outpatients
with obstructive respiratory disease (tab. 1). The healthy lest
subjects and the patients gave informed consent to voluntary
participation in the study.
In normal subjects clearance and distribution volume were
estimated with a Bayesian method (Appendix) using theophyl-
line concentrations obtained after a single test dose as described
below. In addition, for comparison purposes, clearance and
distribution volume were calculated from the area under the
curve.
The volunteers (tab. 1) were administered 42.7 ml theophylline
ethylenediamine solution (= 300 mg theophylline, Euphyllin-
Tropfl sung Byk Gulden, Konstanz, F. R. G.) by timed constant
rate infusion over 20 min. Between 0.25 h and 12 h after the
end of the infusion, theophylline serum concentrations were
determined. For each of the serum concentrations, clearance
and distribution volume were predicted by use of the Bayesian
method. Moreover, in all subjects, these parameters were esti-
mated from theophylline levels determined at 0.25 and 12 h
after drug administration, as well as from all the measured
concentrations. A total of 14 estimates of clearance and distri-
bution volume were obtained for each subject. Prediction error
was calculated by subtraction of clearance (distribution volume)
determined by the area under curve (AUC) method from the
corresponding predicted value (fig. 2, 3). Percental deviation
was calculated as described in the Appendix.
In non-smoking outpatients treated at our hospital blood sam-
ples for theophylline determination were drawn at steady-state
immediately before and l h after administration of the morning
dose. With the Bayesian method individual estimates for clear-
ance and distribution volume were obtained using either the
trough or the 1-h-post-dose theophylline concentration. Indi-
vidual dosage regimens were designed to produce theophylline
serum concentrations of 8 to 20 mg/l. Favourable patient re-
sponses have been reported for theophylline serum concentra-
tion in this range (10). Sustained-release theophylline prepara-
tions (Uniphyllin, Mundipharma Limburg, F. R. G.; Broncho-
retard, Klinge Pharma, M nchen, F. R. G.; PulmiDur, Astra
Chemicals, Wedel/Golstein, F. R. G.; tab. I) were administered
twice-daily, to assess predictive accuracy, steady-state trough
theophylline serum concentrations were measured in each pa-
tient at 8a.m., 14 days after dosage adjustment. Predictive
accuracy was assessed by comparing the. values of predicted
and observed theophylline serum concentrations. Prediction
error was calculated by subtraction of measured from predicted
serum theophyliine concentrations. Based on theoretical con-
L Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 6
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Tab. 1. Patient demographic data.
No. Sex Age
(years)
Weight
(kg)
Height
(cm)
Theophylline dosage/preparation
(mg per day)
Additional
medication
Healthy volunteers
1
2
3
4
5
6
7*
8
9*
10
Hospitalized
R.W.
K.B.
S.H.
Sch. H.
G.G.
K. E.*
S.J.
L.M.
S.G.
F.H.
Outpatients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21'
22"
9
9
<?
9
9
<?
9
9
9
<f
patients
<J
c?
<f
c?
<ί
9
9
<?
9
<5
c?
9
c?
9
S
S
9
9
c?
c?
c?
S
9
9
δ
δ
9
c?
9
c?
(ί
c?
27
26
31
53
30
31
31
40
31
27
77
44
57
49
60
52
55
58
51
65
54
59
74
38
53
58
24
35
61
57
62
63
28
19
67
68
50
76
64
58
54
42
57
58
61
59
75
78
58
63
53
71
78
84
66
87
69
60
58
90
60
92
79
65
75
58
69
95
59
69
81
76
75
75
49
53
91
93
57
73
67
103
79
87
176
160
180
167
172
190
161
172
175
186
176
175
166
180
169
158
156
167
168
185
169
162
172
166
179
178
175
165
177
173
178
182
154
168
169
180
168
172
165
181
169
168
—
—
—
—
—
—
—
—
—
—
1 χ 900 Uniphyllin
1 χ 900 Uniphyllin
1 χ 600 Uniphyllin
1 χ 900 Uniphyllin
1 χ 800 Uniphyllin
2 χ 400 Uniphyllin
2 χ 400 Uniphyllin
2 χ 400 Uniphyllin
2 χ 400 Uniphyllin
2 χ 600 Uniphyllin
2 χ 600 Pulmidur
2 χ 300 Pulmidur
2 χ 400 Uniphyllin
2 χ 500 Bronchoretard
2 χ 500 Bronchoretard
2 χ 450 Pulmidur
2 χ 400 Pulmidur
2 χ 300 Pulmidur
2 χ 500 Bronchoretard
2 χ 450 Pulmidur
2 χ 600 Bronchoretard
2 χ 450 Pulmidur
2 χ 400 Bronchoretard
2 χ 350 Bronchoretard
2 χ 600 Pulmidur
2 χ 500 Bronchoretard
2 χ 400 Bronchoretard
2 χ 500 Bronchoretard
2 χ 500 Bronchoretard
2 χ 500 Bronchoretard
2 χ 500 Bronchoretard
2 χ 500 Bronchoretard
—
—
—
—
—
_
—
—
—
—
A/Dig/N/D
B/C
B/C
C/D
B/C/D
B/C/R
B/C
B/C
B/C/Dox
An/B/C/T
B/C
B/C
An/B/C/N/T
B/C/Dox/tp
B/tp
B/C
B/C/Cr/O
C/T
C/T
B/T
B/C
B/Dig/H
B/C
—
A/B/C/Dig/G/H
Qu/Tr/V
B/C/T
C/T
B/C
B/C/T
B/C
B/C
B/C/S/Trim
(A) - allopurinol, (An) — antihistamine, (B) — -2-sympathomimetics, (C) — corticosteroids, (Cr) — cromoglycidic acid, (D)
— diazepam, (Dig) — digoxin, (Dox) — doxycycline, (G) - glibenclamide, (H) - hydrochlorothiazide, (Tp) - ipratropium-
bromide, (N) — nifedipin, (O) -? oral contraceptives, (Qu) — quinidine, (R) - ranitidine, (S) - sulphamethoxazole, (T) -
terbutaline, (Tr) -* triamterene, (Trim) -* trimethoprim, (V) — verapamil.
(*) — smoker, (I) — acute viral respiratory illness, (II) -- diarrhoea.
siderations (2) the clinically acceptable range for the absolute
prediction error was assumed to be half the width of the
therapeutic range.
Hospitalized patients with obstructive respiratory disease were
administered theophylline (Uniphyllin, Mundiphanna, Lim-
burg, F.R. G.) either as a single evening dose or twice daily
(tab. 1). Blood specimens for theophylline determination were
drawn during steady-state predose and every 3 h during a
dosage interval of 24 or 12 h. Using the Bayesian method,
clearance and distribution volume were estimated in each pa-
tient from a theophylline predose concentration. In addition,
from the observed concentration-time curves, the peak concen-
tration or all theophylline concentrations except the predose
value were used to predict the individual clearance and the
distribution volume. For each patient concentration-time curves
of theophylline were simulated by use of Bayesian estimates for
clearance and distribution volume as described in the Appendix.
Predictive accuracy and precision were assessed as described
above.
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Procedure for estimation of pharmacokinetic param-
eters
Pharmacokinetic parameters (clearance and distribution vol-
ume) were estimated by use of a novel Bayeaan dosage predic-
tion method (Abbott Pharmacokinetic Systems; Theophylline
Program; Abbott Diagnostics, Inc., North Chicago, USA) (see
Appendix for predictive algorithm). The Bayesian program
required input of patient-specific data (age, sex, weight, height,
additional medication, smoking habits, concurrent drug ther-
apy, concomitant diseases), the dosing history and available
theophylline serum concentrations.
Patient-specific data are used to identify the subpopulation to
which the patient belongs. The subpopulation mean estimates
of theophylline clearance can be derived from data collected
from various patient populations (1,11). Initial subpopulation-
based estimates of clearance are generated from an assumed
standard clearance of 40 ml · h"1 · kg"1 for nonsmoking healthy
adults by multiplication with certain factors accounting for
specific patient characteristics (U). The mean population dis-
tribution volume estimate is set at 0.5 I/kg for all patients (7).
Theophylline serum concentrations resulting from a proposed
dosage were simulated with individual estimates for the clear-
ance and the distribution volume, assuming a one compartment
open linear model \with first-order absorption. Individual con-
tributions of each dose were taken into account by use of the
principle of linear superposition (12).
For the sustained-release preparations used in our study, the
average values for the absorption rate constant and bioavaila-
bility are given in table 2.
0.2r
0.1
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tihj
4 6 8 10 12 0.25 0.25
and 12 to 12
Fig. 2. Prediction error of distribution volume in 10 healthy
volunteers after administration of a single theophylline
test dose. Each prediction error is represented as a
horizontal bar. Columns delimit the range. Median of
prediction error is indicated by a horizontal line in each
column. Theophylline serum concentrations used for
each prediction were determined at different times after
the end of the theophylline ethylenediamine infusion as
indicated. Moreover, prediction error was calculated
from distribution volume estimates based on theophyl-
line levels drawn at 0.25 and 12 h after drug adminis^
tration, as well as by use of all concentrations measured
between 0.25 and 12 h.
30 r
Tab. 2. Absorption rate constants and bioavailability of various
sustained-release preparations.
Trade name
Uniphyllin
Bronchoretard
PulmiDur
Absorption rate
constant (ka)
ka = 0.150
ka = 0.289
ka = 0.180
Bioavaila-
bility (F)
F = 0.90
F = 0.88
F = 1.00
Refe-
rences
(31)
(32)
(33)
The employed Bayesian forecasting program was written in C.
It was run on an IBM personal computer XT (512 kb ram)
equipped with an Intel 8087 coprocessor, floppy- and hard disk.
The simulations of concentration-time curves (fig. 6) were run
on a Hewlett-Packard 41 CV programmable calculator using
equation 9 (Appendix).
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Fig. 3. Prediction or clearance in 10 healthy volunteers after
administration of a single theophylline test dose. For
further explanation see legend of fig. 2.
Determinat ion of serum theophylline concentrations
Serum theophylline concentrations were measured by a highly
specific fluorescence polarisation immunoassay (Abbott Theo-
phylline II reagent pack, Abbott Laboratories, North Chicago,
USA) using the TDx Fluorescence Polarisation Immunoassay
(FPIA) System according to the instructions of the manufac-
turer. The lower limit of the measured range was 0.5 mg/1. With
this immunoassay the relative standard deviation between days
was 3.6% over the mid-part of the measuring range (13, 14).
The performance of the FPIA was constantly checked by in-
ternal and external quality control.
Results
The prediction error observed in healthy subjects for
Bayesian estimates of clearance and distribution vol-
ume is given in figures 2 and 3. As expected, the
prediction error depended largely on sampling time.
It was lowest for the distribution volume during the
first 60 min after intravenous theophylline adminis-
tration. For clearance, however, the lowest prediction
error was observed 12 hours after the end of theo-
phylline infusion. With the Bayesian method, clear-
ance determined from a single theophylline concen-
tration was underestimated on average (median) by
4.2 to 15.7 ml - kg~* · h"1 (9.7 to 27.8%) depending
on sampling time. Conversely, distribution volume
was overestimated on average (median) by 0.025 to
0.0951-kg-1 (4.6 to 21.1%).
A° further improvement of clearance prediction was
not achieved, if the prediction was tiased on the initial
and terminal or on all available theophylline concen-
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 6
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trations. In contrast, the predictive accuracy of the
distribution volume was highest when all available
theophylline concentrations were used.
The data show that with only two theophylline con-
centrations taken at the beginning and at the end of
the test period a relatively low prediction error can
volume.
Figure 4 shows the steady-state trough theophylline
serum concentrations which were achieved in 22 non-
smoking outpatients using the Bayesi&n method for
dose prediction. The twice-daily administered main-
tenance doses are also shown. Data from one subject
with acute viral respiratory illness (tab. 1, No. 21)
and a further subject with diarrhoea (tab. 1, No. 22)
were excluded from the statistical evaluation. Based
on clinical considerations target trough concentra-
tions below the therapeutic range were selected in two
patients (tab. 1, No. 8 and No. 17). In these two
patients dosage regimens were designed which resulted
in theophylline concentrations slightly below the ther-
apeutic range. In one patient (tab. 1, No. 7) an un-
expectedly high theophylline serum concentration
above the therapeutic range was found which was not
accompanied by subjective side effects.
With one exception these outpatients showed com-
parable predicted and observed serum theophylline
concentrations. Predictions were either based on a
theophylline level determined 1-h-post-dose (column
A, fig. 4) or on a trough value (column B, fig. 4). The
mean absolute deviations between predicted and ob-
served concentrations were 14.9% (range: 0.0 —
28.9%) and 12.5% (range: 1.3-28.8%) with predic-
tions based on 1-h-post-dose and on trough values
respectively. If predictions were based on the trough
value (column B), there was no significant difference
between the mean value of predicted and measured
theophylline concentration (p > 0.05, paired t-test).
With the 1-h-post^dose value, however, the mean
value (column A) was significant lower than that of
the measured theophylline concentration (p < 0.02,
paired t-test).
Figure 5 shows the prediction error observed by use
of the Bayesian method with 1-h^post-dose value
(shaded column) and trough concentration (clear col^
umn). The mean prediction error is indicated by the
horizontal line in the centre of each column. Vertical
columns represent one standard deviation on either
side of the mean prediction error. If predictions are
to be clinically acceptable, 68% of prediction errors
should fall within the range delimited by broken lines.
The data from our study indicate that in non-smoking
outpatients the predictive accuracy and precision is
25
20
15
r Deviation [%]
A: 14.9±9.3 (0.0-28.9)
B:12.5±8.8 (1.3-28.8)
T
Β
predicted measured
f t
25
20
15
10
5
n
-
f1
Nonsmokers
(n-20)
Fig. 4. Comparison between predicted and measured trough
steady-state theophylline serum concentrations in 20
non-smoking outpatients. Column A represents theo-
phylline trough concentrations predicted from 1 -h-post-
dose values and column B those predicted from trough
concentrations. The daily administered theophylline
maintenance dose is also given. The columns show the
mean values with standard deviation (vertical bars) and
range (triangles). Mean deviation (%) between predicted
and observed concentration was calculated as described
in the Appendix.
ι 2
1 0
3 -2
-6-
Nonsmokers
Fig. 5; Prediction errors (predicted minus measured values) for
trough steady-state serum theophylline concentrations
observed in 22 non-smoking outpatients. Predictions
were performed by use of 1-h-post-dose value (shaded
column) and the trough value respectively (clear col-
umn). The columns delimit one standard deviation on
either side of the mean prediction error indicated by the
horizontal line in each column. The horizontal bars
represent the observed individual prediction errors. The
broken lines ( ) delimit the clinically acceptable
range for one standard deviation of the prediction error.
Two patients were excluded from the statistical evalu-
ation:
·—· patient with acute viral respiratory illness,
ο—ο patient with diarrhoea.
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clinically acceptable. Mean values of predicted theo-
phylline serum concentrations were slightly lower than
averaged observed concentrations (fig. 4). The cor-
responding mean prediction errors were —1.2 mg/1
and —0.6 mg/1 for predictions based on the 1-h-post-
dose and the trough values, respectively (fig. 5).
As expected, relatively large prediction errors were
observed for the two patients excluded from the study
because of diarrhoea and viral infection (fig. 5). The
patient who developed an unexpectedly high theo-
phylline concentration also showed a large prediction
error of —6.6 mg/1 and —6.9 mg/1, respectively
(fig. 5).
In hospitalized patients, the observed and predicted
concentration-time curves of steady-state theophylline
serum concentrations were compared (fig. 6). In pa-
tients who received a sustained-release theophylline
preparation (Uniphyllin) twice-daily, all but one of
the observed theophylline concentrations were in
good agreement. Prediction error ranged from 2.4
mg/1 to -2.4 mg/1. In patient S.C., who showed a
noticeable lag-phase, prediction errors between 4.6
mg/1 and -2.0 mg/1 were found.
If, however, theophylline was given as a single evening
dose, a reliable prediction of the subsequent concen-
tration-time curve was not possible. Predictions from
trough concentrations resulted in a substantial under-
estimation of peak concentrations. Prediction errors
ranged from 4.8 mg/1 to - 5.8 mg/1 in patients without
lag-phase. In these cases prediction error tended to
decrease during the second half of the dosage interval.
In addition, predictive accuracy was tested, using
theophylline concentrations of the represented con-
centration-time curves. If the prediction of the con-
centration-time curves was based on the observed
theophylline peak concentrations, the prediction error
was relatively low for peak concentrations (range:
—0.2 mg/1 to -2.1 mg/1) and comparatively high for
trough concentrations (range: 7.3 mg/1 to 1.6 mg/1).
Even if all theophylline concentrations observed after
dosage administration were used, predicted and ob-
served concentration-time curves were largely discrep-
ant. In one patient (Sch. H.) an extensive lag-phase
occurred, rendering a dosage prediction impossible.
In table 3 Bayesi&n estimates for clearance and dis-
tribution volume are shown. In each hospitalized pa-
tient receiving theophylline twice-daily, estimates for
these parameters were in good agreement irrespective
of whether trough, peak or all theophylline concen-
trations after dose administration were used for pre-
diction. In patients treated with high single evening
doses, clearance estimates from trough concentrations
were significantly higher than those resulting from
Tab. 3. Bayesian estimates for clearance and distribution vol-
ume obtained in hospitalized patients treated with a
sustained-release theophylline preparation (Uniphyl-
lin).
Patient Clearance
(ml · kg'1 · h-1)
r Distribution
volume (1 · kg-1)
Pb
Twice daily dosage
K.E.
S.J.
L.M.
S.C.+
F.H.
49.08
55.96
53.05
55.27
27.84
42.76
49.51
47.65
49.65
28.11
45.39
53.90
55.97
54.16
27.45
0.54
0.54
0.64
0.50
0.54
0.53
0.54
0.62
0.51
0.54
0.47
0.52
0.59
0.53
0.54
x: 46,48 42.01 45.68 x: 0.57 0.56 0.53
Single evening dosage
R.W.
K.B.
S.H.
Sch.H.+
G.G.
31.35
60.95
67.76
53.74
80.73
x: 60.20
24.26
37.67
35.48
37.37
52.07
37.37*
27.18
49.87
47.12
44.00
63.29
46.87*
0.53
0.54
0.53
0.49
0.50
x: 0.53
0.53
0.56
0.55
0.50
0.53
0.54
0.51
0.41
0.61
0.55
0.45
0.50
(*) — Differs significantly from the corresponding prediction
based on the trough value (p < 0.05 paired t-test)
(ta) — Estimation from trough value
(pb) — Estimation from peak value
(ac) — Estimation from all observed values after dosage admin-
istration
(+) — Patients with lag-phase; values excluded from statistical
evaluation
peak concentrations. Bayenan estimates for distri-
bution volume obtained by using the trough, the peak
or all the theophylline concentrations showed no sig-
nificant differences.
Discussion
In recent years the use of individualized dosage regi-
mens has gained increasing importance in the long
term treatment of asthma with theophylline. The
pharmacokinetic variability observed with theophyl-
line makes individual dosage adjustment difficult.
Therefore the monitoring of theophylline serum con-
centrations has become current practice. In addition
various methods have been proposed for dosage pre-^
diction (2-9, 15, 16). Single point methods (6, 9, 15,
16) which may be used without a computer have the
disadvantage that they can only be used at the very
beginning of the treatment.
Our study shows, that the Bayesian approach is more
flexible, as it allows dosage predictions at any time
during theophylline therapy. However, data from our
single dose study (figs. 2 and 3) and from ambulatory
patients with twice-daily maintenance regimens (figs;
4 and 5) demonstrate that the predictive accuracy
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 6
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Fig. 6. Comparison between predicted (ο—ο from predose value, α —ρ from peak value, Δ — Δ by use of all values with
exception of the predose value) and measured (A — A ) steady-estate serum theophylline concentrations in hospitalized
patients with obstructive lung disease.
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depends on the time of blood sampling. Serum con-
centrations taken during the initial distribution period
yielded a lower prediction error for distribution vol-
ume, whereas concentrations taken during the ter-
minal elimination period resulted in a lower prediction
error for clearance (figs. 2 and 3).
An appropiate sampling time must be clinically prac-
ticable and ensure a sufficient predictive accuracy.
Therefore, outpatients were investigated to ascertain
whether the trough or the 1-h-post-dose theophylline
concentration would be more convenient. It was
found that with the trough theophylline serum con-
centration a significantly higher predictive accuracy
could be obtained than with the 1-h-post-dose value
(fig. 4 and 5). It appeared not to be reasonable to use
both values, since due to the time-dependent weight-
ing of measured theophylline concentrations the
Bayesian pharmacokinetic parameter estimates are
primarily based on the most recently determined val-
ues (8). It is to be expected that an increased predictive
accuracy can be achieved, if a trough concentration
in combination with the preceding 1-h-post-dose value
of the same dosage interval is used. In outpatients,
however, this would not be practical, since the patients
would have to return to the clinic.
The results of our study demonstrate that the Bayes-
ian forecasting method permits the prediction of theo-
phylline serum concentrations in outpatients with a
clinically acceptable prediction error. This applies,
however, only to twice-daily dosage regimens with the
sustained-release theophylline preparations used in
our study.
Relatively large prediction errors were observed in 3
outpatients, presumbably due to changes in clearance
(tab. 1, No. 21), altered absorption (tab. 1, No. 22)
and non-linear kinetics (tab. 1, No. 7).
In hospitalized patients with twice-daily maintenance
regimens, the concentration-time curves of theophyl-
line could generally be predicted with sufficient ac-
curacy. Patients with once-daily dosing, however,
showed much larger fluctuations between peak and
trough theophylline concentrations in serum than
those treated with twice-daily doses (fig. 6). In this
group of patients, clearance estimates from trough
theophylline concentrations were significantly higher
than those obtained with peak concentrations (tab.
3). This finding points to a non-linearity of theo-
phylline kinetics in these patients. Also other inves-
tigators (17—21) have observed that the pharmaco-
kinetics of theophylline may be non-linear in certain
individuals.
Considering the relatively high evening doses it may
be speculated that a saturation of theophylline kinet-
ics occurred. Since dosage regimens with high single
daily doses are increasingly used in patients with
nocturnal asthma (22, 23), problems due to dose-
dependent theophylline kinetics will be encountered
more often in clinical practice. 'Therefore caution
should be exercised when using drug dosing programs
based on linear kinetics for individualization of theo-
phylline therapy.
In a different recent study dealing with once daily
dosing, Chrystyn et al. (34) reported on some loss of
precision in the prediction of peak theophylline con-
centrations using Bayesian estimates derived from the
24 h post-dose values. For practical purposes sam-
pling times between 12 and 18 h post dose were sug-
gested by these authors for patients receiving theo-
phylline once daily.
Further problems arise from altered absorption. In
two of the 10 hospitalized patients (tab. 1 and fig. 6:
S. C. and Seh. H-) a lag-phase was observed, which,
in one of these cases (Sch. H.), rendered an appropri-
ate dosage prediction impossible.
In order to avoid problems arising from dose-de-
pendent theophylline kinetics, Bayesian methods in-
volving Michaelis-Menten kinetics should be devel-
oped. Such procedures have already been described
for phenytoin (24—26).
Furthermore, from theoretical considerations the
Bayesian method as used in our study has certain
disadvantages. The posterior distribution does not
belong to the same class as the prior distribution (i. e.
normal distribution). The mode of the distribution
can be calculated only approximately with iterative
procedures (27, 28) and does not coincide with the
mean or median of the distribution. If serum theo-
phylline concentration measurements of an individual
patient are used in the posterior distribution, the mode
can be considered as the best "estimate" of this in-
dividual patient's pharmacokinetic parameters from
prior population-specific information and actual drug
level measurements. Both disadvantages result from
the fact that the pharmacokinetic function is non-
linear in the parameters. An alternative Bayesian ap-
proach, which may avoid these problems, has recently
been suggested (8).
The practicability of the Bayesian method tested is
acceptable. The time needed to perform a dosage
prediction is about 10 to 15 minutes, provided that
all necessary data are available.
In conclusion, the clinical application of the tested
Bayesian forecasting method appears to be promising.
The user of this program, however, must be aware of
the discussed limitations.
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Appendix
In the employed drug dosing program an algorithm
is used, which represents an application of the Bayes
formula (29) to phannacokinetic parameter estima-
tion. This formula uses as "mediator" between the a
priori and a posteriori distribution, the likelihood. If
we denote the prior distribution (density) of the pa-
rameter ρ with q (p), the likelihood (density) of the
measurement c for a given parameter value ρ with
f(c/p) and the posterior distribution (density) with
g(p/c), Bayes formula reads:
j Σ (q - c*(tj; PL ... pn))2
g(p/c) = f(c/p) · g(p)h(c) (Eq. 1)
The denominator h (c) is the "unconditional" distri-
bution (density) of c and is calculated as:
h(c)=Jf(c/p)q(p)dp,
where integration is done over the range of p.
The application of this approach to phannacokinetic
parameter estimation is straightforeward:
Suppose that in a pharmacokinetic study with an
individual (e. g. patient or volunteer) at times tt, ... tm
serum concentrations cly ... cm of some compound are
measured and these measurements c\ can be additively
decomposed in a functional term c*(tj; pt,... pn) (de-
pending on n individual kinetic parameters pi} ... pn)
and an error term e» (residual plasma concentration-
error):
d = £*(t,·; PI, ... pn) + (Eq.2)
The functional term may be a feasible expression for
the time-course of the serum concentrations; e. g. the
open one-compartment function:
,,p2) = P, e-»1 (Eq.3)
for a bolus injection or the Bateman function:
c*(t; PI, p2, p3) = (Eq.4)
for oral application, where pj is a function of the
dose,"bioavailability and distribution volume, p2 the
elimination constant (clearance divided by volume of
distribution) and p3 the apparent first order absorp-
tion rate.
Usually it is assumed that the eg are realisations of
independent, normally distributed random variables
with mean 0 and variance σ*. With this assumption
the q are — for fixed parameter values pi, ... pn —
realisations of independent, normally distributed ran-
dom variables with mean c*(tij p,,... pn) and variance
cl; so the likelihood is:
(2Π)ϊ
(Eq. 5)
For prediction purposes one can assume that the
parameters as well as the residual variance depend on
further parameters or patient characteristics like sex,
age or state of illness; but for the moment we neglect
these dependencies.
It seems reasonable to assume as prior distribution of
the parameters PJ a multivariate normal distribution
with some assumed mean vector:
t , . . . Pi) (Eq. 6)
and covariance matrix sp. If, in a first attempt, the
parameters are assumed as independent (which is not
a feasible assumption) the covariance matrix reduces
to a diagonal matrix with the variances Gp. as diagonal
elements, and the a priori distribution is simply:
(Eq.7)
(2Π)3
Both assumptions lead — according to Bayes formula
— to the a posteriori distribution density whose log-
arithm is proportional to:
(c, - c*(tj; p,, . .. pn))2 (Eq.8)
It should be remarked that this a posteriori distribu-
tion is not a normal distribution and the parameters
PJ are a posteriori dependent, in spite of the a priori
independence assumption.
The detailed derivation of this algorithm and its ap-
plication in the drug dosing program has recently
been described (8).
For the simulation of concentration time profiles (fig.
6) the following equation was used:
c« =
k a F :
Vd(ka -
. 9)
where c«> denotes the serum steady-state drug con-
centration at time t during a dosing interval τ, F is
the fraction of the administered dose Dm, which is
absorbed, Vd is the distribution volume, while Kc and
ka are the elimination rate constant and the absorp-
tion rate constant, respectively.
For calculation of the theophylline clearance (1 · h"1)
and distribution volume (1) of the hospitalized patients
the lean body weight (30) was used.
1
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Mean (median) % deviation was calculated from the D =
absolute values of percental deviation (D) observed
in each individual:
p — m
m
100 (Eq. 10)
where p is the predicted value and m the measured
value.
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